[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201800394WA - Novel endos mutant enzyme - Google Patents

Novel endos mutant enzyme

Info

Publication number
SG11201800394WA
SG11201800394WA SG11201800394WA SG11201800394WA SG11201800394WA SG 11201800394W A SG11201800394W A SG 11201800394WA SG 11201800394W A SG11201800394W A SG 11201800394WA SG 11201800394W A SG11201800394W A SG 11201800394WA SG 11201800394W A SG11201800394W A SG 11201800394WA
Authority
SG
Singapore
Prior art keywords
novel
mutant enzyme
endos mutant
endos
enzyme
Prior art date
Application number
SG11201800394WA
Inventor
Yoshirou KAWAGUCHI
Kensuke Nakamura
Yukiko Sekiguchi
Mitsuhiro Iwamoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11201800394WA publication Critical patent/SG11201800394WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201800394WA 2015-07-16 2016-07-15 Novel endos mutant enzyme SG11201800394WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015141901 2015-07-16
PCT/JP2016/070921 WO2017010559A1 (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme

Publications (1)

Publication Number Publication Date
SG11201800394WA true SG11201800394WA (en) 2018-02-27

Family

ID=57757160

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201800394WA SG11201800394WA (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme
SG10201914047RA SG10201914047RA (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201914047RA SG10201914047RA (en) 2015-07-16 2016-07-15 Novel endos mutant enzyme

Country Status (11)

Country Link
US (1) US11001819B2 (en)
EP (1) EP3323886B1 (en)
JP (1) JP6752203B2 (en)
KR (1) KR102546854B1 (en)
CN (1) CN108026518B (en)
AU (1) AU2016294206B9 (en)
ES (1) ES2848861T3 (en)
HK (1) HK1248271A1 (en)
SG (2) SG11201800394WA (en)
TW (1) TWI730972B (en)
WO (1) WO2017010559A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. Glycan arrays and method of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3436482A4 (en) 2016-03-29 2020-03-11 OBI Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109379889A (en) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 Pass through the immune activation or immunoregulatory immunotherapy for cancer via GLOBO series antigen
EP4159749A3 (en) 2016-07-01 2023-06-14 Daiichi Sankyo Company, Limited A method for producing fc-containing molecule with remodeled sugar chain
CN110062767B (en) 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 Human antibodies, pharmaceutical compositions and methods
US11208442B2 (en) 2016-12-02 2021-12-28 Daiichi Sankyo Company, Limited Endo-beta-N-acetylglucosaminidase
US11628223B2 (en) 2017-09-29 2023-04-18 Daiichi Sankyo Company, Limited Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
TW202031298A (en) 2018-11-14 2020-09-01 日商第一三共股份有限公司 Anti-cdh6 antibody-pyrrolobenzodiazepine derivatives conjugate
JPWO2020196474A1 (en) 2019-03-25 2020-10-01
WO2020196475A1 (en) 2019-03-25 2020-10-01 第一三共株式会社 Anti-her2 antibody-pyrrolobenzodiazepine derivative conjugate
US20220168438A1 (en) 2019-03-27 2022-06-02 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
JP7449591B2 (en) * 2019-08-05 2024-03-14 チョ ファーマ インコーポレイテッド Fusion proteins for remodeling antibody glycoforms
AU2020420236A1 (en) 2020-01-10 2022-09-01 Fushimi Pharmaceutical Co., Ltd. Population of antibodies comprising homogeneous antibodies each having left-right asymmetric sugar chains, and method for producing same
CN118562771A (en) * 2020-06-18 2024-08-30 上海宝济药业股份有限公司 Mutant of immunoglobulin degrading enzyme IdeE
KR20230061360A (en) 2020-09-02 2023-05-08 다이이찌 산쿄 가부시키가이샤 Novel endo-β-N-acetylglucosaminidase
JPWO2022211075A1 (en) * 2021-03-31 2022-10-06
WO2023136342A1 (en) 2022-01-17 2023-07-20 第一三共株式会社 Tsp1 inhibitor
WO2023167238A1 (en) 2022-03-02 2023-09-07 第一三共株式会社 METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
CN118325869B (en) * 2024-06-12 2024-10-22 上海盛迪医药有限公司 Endo-beta-N-acetylglucosidase variant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101889082A (en) * 2007-09-14 2010-11-17 季诺维斯公司 Method and kits for dissociating Fcgamma-receptor-IgG complexes and for igg purification and detection
WO2013012066A1 (en) * 2011-07-21 2013-01-24 京セラ株式会社 Lighting device, image sensor head and reading device provided with same
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
JP6282232B2 (en) 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア Enzymatic chemical glycosylation of antibodies and Fc fragments thereof

Also Published As

Publication number Publication date
EP3323886B1 (en) 2020-10-21
HK1248271A1 (en) 2018-10-12
AU2016294206B2 (en) 2021-12-02
EP3323886A4 (en) 2019-02-27
TW201708540A (en) 2017-03-01
US11001819B2 (en) 2021-05-11
KR102546854B1 (en) 2023-06-22
KR20180030536A (en) 2018-03-23
CN108026518A (en) 2018-05-11
EP3323886A1 (en) 2018-05-23
AU2016294206B9 (en) 2021-12-23
TWI730972B (en) 2021-06-21
AU2016294206A1 (en) 2018-02-08
US20180208915A1 (en) 2018-07-26
JPWO2017010559A1 (en) 2018-04-26
JP6752203B2 (en) 2020-09-09
SG10201914047RA (en) 2020-03-30
CN108026518B (en) 2022-09-06
WO2017010559A1 (en) 2017-01-19
ES2848861T3 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
HK1248271A1 (en) Novel endos mutant enzyme
EP3133960A4 (en) Improved mattress
EP3172993A4 (en) Pillow
EP3297586A4 (en) Oral appliance
EP3222714A4 (en) Phytase mutants
EP3310314A4 (en) Lift-assist chair
EP3270738A4 (en) Mattress
EP3438253A4 (en) Phytase mutant
EP3374718A4 (en) Coldwave appliance
EP3037812C0 (en) Enzyme electrode
LT3256486T (en) Griffithsin mutants
EP3399007A4 (en) Gasification furnace
EP3354988A4 (en) Cooker
EP3346188A4 (en) Cooker
EP3360427A4 (en) Cooked-rice improver having flavor improving action
EP3343110A4 (en) Cooker
EP3322324A4 (en) Cleaning pad
EP3318167A4 (en) Cleaner
EP3099199A4 (en) Self-adjusting bed
EP3114968A4 (en) Height-adjustable pillow
EP3128004A4 (en) Enzyme agent
ZA201608406B (en) Enzyme treatment composition
EP3285546A4 (en) Cooker
EP3362755B8 (en) Furnace
EP3185823A4 (en) Oral appliance